In conclusion, our study supports the hypothesis that TIGIT may play a more important role as an immune checkpoint in MM than PD-1 and CTLA-4, and that anti-TIGIT mAbs could be effective in MM. The gene discussed is TIGIT; the disease is Miyoshi myopathy.